Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

Main Study Inclusion Criteria:

• Diagnosis of irritable bowel syndrome (IBS) with predominant constipation (IBS-C) orpredominant diarrhea (IBS-D) according to Rome IV criteria at Visit 1 (Screening)

• Per the Rome IV diagnostic algorithm for IBS, participants 50 years of age and overare to have had one of the following with a result that rules out causes ofabdominal pain other than IBS:

1. Colonoscopy (within 10 years of Visit 1 [Screening])

2. Flexible sigmoidoscopy and double contrast barium enema (within 5 years ofVisit 1 [Screening])

3. Computed tomography colonography (within 5 years of Visit 1 [Screening])

Main Study Exclusion Criteria:

• Diagnosis of IBS with mixed bowel habits (IBS-M) or unsubtyped IBS (IBS-U)

• Clinically relevant changes in dietary, lifestyle, or exercise regimen within 30days prior to Visit 1 (Screening) that may confound efficacy assessments in theclinical judgment of the Investigator (or designee)

• Any colonic or major abdominal surgery (eg, bariatric surgery [including gastricbanding], stomach surgery, small/large bowel surgery, or abdominal large vesselsurgery). History of cholecystectomy is exclusionary for participants with IBS-D.For participants with IBS-C, a history of cholecystectomy more than 6 months priorto Visit 1 (Screening) is allowed. Procedures such as appendectomy, hysterectomy,caesarean section, or polypectomy are allowed as long as they have occurred at least 3 months prior to Visit 1 (Screening).

Long-Term Extension Inclusion Criteria:

•All participants must have completed the Main Study (including both Visit 8 [Week 12] and Visit 9 [Week 14])

Long-Term Extension Exclusion Criteria:

• Participant meets any exclusion criteria from the Main Study at the time ofassessing eligibility for the LTE, unless approved by the Sponsor in advance.

• Participant had less than 75% overall compliance with eDiary entries during the MainStudy.

• Participant deviated from the prescribed dosage regimen during the Main Study (ie,overall study treatment compliance less than 85% or more than 115%), unless approvedby the Sponsor in advance.